SynCore Biotechnology Announces Interim Analysis Results for Novel Pancreatic Cancer Asset, SB05PC (EndoTAG®-1)
SynCore Biotechnology (4192:TT) receives interim analysis results for its global phase III clinical trial, SB05PC [...]
SB05 Pancreatic Cancer Clinical Trial Reaches Conditions to Conduct Interim Analysis
SynCore’s global phase III clinical trial on pancreatic cancer second-line therapy, SB05PC (EndoTAG®-1) has reached [...]
SB05PC (EndoTAG®-1) Phase III been Approved in China by NMPA
China NMPA Approves SynCore Biotechnology to Conduct Phase III Human Clinical Trial for SB05PC (EndoTAG®-1), [...]
SynCore Bio Enrolled First Patient In Phase III Trial for SB05 Pancreatic Cancer in Hungary
Taipei, Taiwan, 14 January 2019. SynCore Biotechnology Co. (4192:TT) announces first patient in for phase III [...]
SynCore Bio Doses First Patient In Phase III Trial for SB05 Pancreatic Cancer in South Korea
Taipei, Taiwan, 25 December 2018. SynCore Biotechnology Co. (4192:TT) announces first patient in for Phase [...]
SB05 PC is Approved to Conduct Phase III Clinical Trial for Pancreatic Cancer in Israel
SB05 (EndoTAG®-1) is approved to conduct Phase III clinical trial for pancreatic [...]
SB05 PC is Approved to Conduct Phase III Clinical Trial for Pancreatic Cancer in Russia
SB05 (EndoTAG®-1) is approved to conduct Phase III clinical trial for pancreatic cancer in Russia by [...]
SynCore Biotechnology has Received the Approval to Conduct SB05 PC for Phase III Clinical Trial in South Korea
SB05 (EndoTAG®-1) is approved to conduct Phase III clinical trial in South Korea (MFDS) for pancreatic cancer. [...]
SB05 PC for Pancreatic Cancer is Approved to implement Phase III Clinical Trial in Hungary
SynCore Biotechnology has received the approval from OGYEI to conduct Phase III clinical trial for its drug [...]
SynCore Bio Signs Agreement with British Company Epipole to Distribute Eye Disease Diagnosis Fundus Cameras in Taiwan
SynCore Biotechnology Co. Ltd. (4192) signed an international contract with UK-based retinal imaging company Epipole [...]